Compare WCC & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WCC | ASND |
|---|---|---|
| Founded | 1922 | 2006 |
| Country | United States | Denmark |
| Employees | 21000 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 14.7B |
| IPO Year | N/A | 2014 |
| Metric | WCC | ASND |
|---|---|---|
| Price | $350.40 | $228.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $271.50 | ★ $281.50 |
| AVG Volume (30 Days) | 472.5K | ★ 744.9K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.38 | $96.35 |
| Revenue Next Year | $5.42 | $44.91 |
| P/E Ratio | $23.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $156.28 | $151.11 |
| 52 Week High | $330.00 | $250.74 |
| Indicator | WCC | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 72.31 | 48.12 |
| Support Level | $246.56 | $214.92 |
| Resistance Level | N/A | $236.58 |
| Average True Range (ATR) | 10.34 | 7.66 |
| MACD | 1.29 | -2.04 |
| Stochastic Oscillator | 89.91 | 36.96 |
Wesco can be traced back to the late 1800s but was officially founded in 1922, acting as the distribution arm of Westinghouse Electric. Throughout the 1900s, Wesco entered and subsequently exited the consumer electronics, transit, bottling, and nuclear plant distribution markets. It was sold to a private equity firm in 1994 and then went public in 1999, and numerous acquisitions have since been made to fill the gaps in Wesco's geographical and product coverage. Today, the firm primarily distributes electrical, networking, security, and utility equipment used in the construction and repair of structures such as offices, data centers, power transmission lines, and manufacturing plants. Wesco has operations around the globe but generates the majority of its revenue in the United States.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.